Intellia Therapeutics (NTLA) Return on Capital Employed (2016 - 2026)
Intellia Therapeutics (NTLA) reported Return on Capital Employed of 58.11% for Q1 2026, down 267.0% year-over-year from 34.8% in Q1 2025, and down 2.76% on a QoQ basis from 56.55% in Q4 2025.
Intellia Therapeutics (NTLA) has 11 years of Return on Capital Employed data on file, last reported at 58.11% in Q1 2026.
- Quarterly Return on Capital Employed fell 267.0% year-over-year to 58.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58.11% (down 267.0% YoY) and the FY2025 annual result came in at 48.32%, down 125.0% from the prior year.
- Return on Capital Employed slipped to 58.11% in Q1 2026 per NTLA's latest filing, from 56.55% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 31.19% in Q1 2023 and bottomed at 60.45% in Q2 2025.
- The 5-year median for Return on Capital Employed is 44.54% (2023), against an average of 46.25%.
- The widest annual swing landed in 2022, when Return on Capital Employed tumbled 1898 bps; it then jumped 359 bps in 2023.
- Tracing NTLA's Return on Capital Employed over 5 years: stood at 38.97% in 2022, then dropped by 14 bps to 44.54% in 2023, then dropped by 12 bps to 49.87% in 2024, then retreated by 13 bps to 56.55% in 2025, then dropped by 3 bps to 58.11% in 2026.
- Per Business Quant, the three latest NTLA Return on Capital Employed figures stand at 58.11% (Q1 2026), 56.55% (Q4 2025), and 58.5% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -58.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.11% |
| Dec 31, 2025 | -56.55% |
| Sep 30, 2025 | -58.50% |
| Jun 30, 2025 | -60.45% |
| Mar 31, 2025 | -55.44% |
| Dec 31, 2024 | -49.87% |
| Sep 30, 2024 | -49.94% |
| Jun 30, 2024 | -46.77% |
| Mar 31, 2024 | -43.75% |
| Dec 31, 2023 | -44.54% |
| Sep 30, 2023 | -40.75% |
| Jun 30, 2023 | -36.19% |
| Mar 31, 2023 | -31.19% |
| Dec 31, 2022 | -38.97% |
| Sep 30, 2022 | -44.34% |
| Jun 30, 2022 | -38.24% |
| Mar 31, 2022 | -32.58% |
| Dec 31, 2021 | -22.53% |
| Sep 30, 2021 | -25.37% |
| Jun 30, 2021 | -29.96% |
| Mar 31, 2021 | -23.58% |
| Dec 31, 2020 | -27.14% |
| Sep 30, 2020 | -29.60% |
| Jun 30, 2020 | -35.26% |
| Mar 31, 2020 | -39.97% |
| Dec 31, 2019 | -34.89% |
| Sep 30, 2019 | -31.20% |
| Jun 30, 2019 | -31.01% |
| Mar 31, 2019 | -30.09% |
| Dec 31, 2018 | -30.94% |
| Sep 30, 2018 | -31.14% |
| Jun 30, 2018 | -26.69% |
| Mar 31, 2018 | -23.09% |
| Dec 31, 2017 | -24.72% |
| Sep 30, 2017 | -24.07% |
| Jun 30, 2017 | -19.32% |
| Mar 31, 2017 | -14.54% |
| Dec 31, 2016 | -11.93% |
| Sep 30, 2016 | -9.47% |
| Jun 30, 2016 | -13.08% |
| Mar 31, 2016 | -27.86% |